Industry ExaminerWhy did Biogen pay up for Apellis Pharmaceuticals?
Because this may be less about buying a drug and more about buying a nephrology platform.
Our latest argues that kidney disease is starting to look like biotech’s next strategic battleground, and that Biogen’s Apellis deal may be an early signal of where the industry is heading.
Read more: https://biotech.industryexaminer.com/biogen-apellis-kidney-disease-nephrology-biotech/
